A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.
Becker PS et al. Blood Cancer J. 2016 May 13;6:e422. doi: 10.1038/bcj.2016.31.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.
Green DJ et al. Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.123. [Epub ahead of print].

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.
Merz M et al. Eur J Cancer. 2016 May 10;62:1-8. doi: 10.1016/j.ejca.2016.04.004. [Epub ahead of print].

Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.
Sweiss K et al. Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.136. [Epub ahead of print].

Effect of Melphalan 140 mg/m2 versus 200 mg/m2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation – A single center experience.
Katragadda L et al. Clin Transplant. 2016 May 24. doi: 10.1111/ctr.12762. [Epub ahead of print].

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE et al. Biol Blood Marrow Transplant. 2016 May 7. pii: S1083-8791(16)00190-7. doi: 10.1016/j.bbmt.2016.03.021. [Epub ahead of print].

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUSTM (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos MA et al. Blood. 2016 May 25. pii: blood-2016-02-700872. [Epub ahead of print].

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ et al. Cancer. 2016 May 18. doi: 10.1002/cncr.30026. [Epub ahead of print].

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Moreau P et al. Leuk Lymphoma. 2016 May 13:1-8. [Epub ahead of print].